"This grant is a significant achievement for Mount Sinai, propelling us to the forefront of personalized medicine and its application in the clinical setting," said Dennis. S. Charney, MD, Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs of The Mount Sinai Medical Center. "The future of medicine lies in genomics research and translating it into a patient-care setting. Mount Sinai's commitment to translational research makes us uniquely poised to lead that revolution."
Mount Sinai Biobank patients have provided DNA and plasma samples to aid in genomic and personalized medicine research, allowing Dr. Bottinger's team to validate and customize 288 previously-reported single nucleotide polymorphisms (SNPs) as genetic risk markers of major diseases, including heart, kidney, and liver disease, for Mount Sinai's racially and ethnically diverse patient populations. The IPM team is committed to ensuring that this information is made available in culturally appropriate, easy to understand formats, and will have the potential to benefit all patients.
The IPM research team will create a Biobank database that will have each of these individual's genetic-disease risk profiles for heart, kidney, and liver disease, as well as their likely response to different medications and potential side effects data that will be entered into Mount Sinai's electronic medical record system for patients who consent to participate in this new study.
The study will include one group of physicians and patients that will be randomized to a genomic-risk assessment, and another that will be randomized to a traditional risk assessment, using risk factors like cholesterol and high blood pressure when determining a patient's risk for heart disea
|Contact: Mount Sinai Press Office|
The Mount Sinai Hospital / Mount Sinai School of Medicine